MedPath

Allantoin

Generic Name
Allantoin
Brand Names
Allegra Cooling Relief Anti-itch, Anbesol Cold Sore Therapy, Mederma Advanced Scar
Drug Type
Small Molecule
Chemical Formula
C4H6N4O3
CAS Number
97-59-6
Unique Ingredient Identifier
344S277G0Z
Background

Allantoin is a substance that is endogenous to the human body and also found as a normal component of human diets . In healthy human volunteers, the mean plasma concentration of allantoin is about 2-3 mg/l. During exercise, the plasma allantoin concentration rapidly increases about two fold and remains elevated . In human muscle, urate is oxidized to allantoin during such exercise . The concentration of allantoin in muscles increases from a resting value of about 5000 ug/kg to about 16000 ug/kg immediately after short-term exhaustive cycling exercise .

More specifically, allantoin is a diureide of glyoxylic acid that is produced from uric acid. It is a major metabolic intermediate in most organisms. Allantoin is found in OTC cosmetic products and other commercial products such as oral hygiene products, in shampoos, lipsticks, anti-acne products, sun care products, and clarifying lotions . Allantoin has also demonstrated to ameliorate the wound healing process in some studies .

Indication

Allantoin is commonly applied in a variety of topical vehicles or applications such as cosmetic creams, toothpastes, mouthwashes, shampoos, lipsticks, anti-acne products, and lotions for the purpose of moisturizing skin, enhancing the smoothness of skin, stimulating the healing of wounds, and soothing irritated skin .

Associated Conditions
Scarring
Associated Therapies
Dental cleaning therapy, Skin Lightening, Skin protection

Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab

Phase 1
Recruiting
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2024-11-29
Last Posted Date
2025-02-11
Lead Sponsor
University of California, San Diego
Target Recruit Count
20
Registration Number
NCT06710223
Locations
🇺🇸

University of California, San Diego, San Diego, California, United States

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

Phase 1
Recruiting
Conditions
Locally Advanced Pancreatic Adenocarcinoma
Interventions
Biological: anti-PD-1
First Posted Date
2022-11-07
Last Posted Date
2024-03-08
Lead Sponsor
TriSalus Life Sciences, Inc.
Target Recruit Count
60
Registration Number
NCT05607953
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Phase 1
Active, not recruiting
Conditions
Hepatocellular Carcinoma
Intrahepatic Cholangiocarcinoma
Interventions
Biological: Pembrolizumab
Biological: Nivolumab
Biological: Ipilimumab
First Posted Date
2022-02-02
Last Posted Date
2023-12-26
Lead Sponsor
TriSalus Life Sciences, Inc.
Target Recruit Count
89
Registration Number
NCT05220722
Locations
🇺🇸

University of Colorado, Aurora, Colorado, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Columbia University, New York, New York, United States

and more 1 locations

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Phase 1
Active, not recruiting
Conditions
Metastatic Uveal Melanoma in the Liver
Interventions
Biological: Nivolumab
Biological: Ipilimumab
Biological: Nivolumab and Relatlimab
First Posted Date
2021-06-22
Last Posted Date
2024-03-06
Lead Sponsor
TriSalus Life Sciences, Inc.
Target Recruit Count
80
Registration Number
NCT04935229
Locations
🇺🇸

UCLA, Los Angeles, California, United States

🇺🇸

Stanford, Stanford, California, United States

🇺🇸

Washington University, Seattle, Washington, United States

and more 7 locations

UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma

Phase 1
Completed
Conditions
Advanced Solid Tumors
Lymphoma
Interventions
Radiation: Radiotherapy
First Posted Date
2017-10-26
Last Posted Date
2022-02-01
Lead Sponsor
University of California, Davis
Target Recruit Count
20
Registration Number
NCT03322384
Locations
🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Phase 2
Active, not recruiting
Conditions
Prostatic Neoplasms
Interventions
First Posted Date
2017-01-02
Last Posted Date
2024-12-06
Lead Sponsor
David Oh
Target Recruit Count
23
Registration Number
NCT03007732
Locations
🇺🇸

University of California San Francisco, San Francisco, California, United States

Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)

Phase 1
Terminated
Conditions
Neoplasms, Advanced
Interventions
Biological: MK-1966
First Posted Date
2016-04-07
Last Posted Date
2019-02-04
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
14
Registration Number
NCT02731742

The Efficacy of Extract of Allium Cepae, Allantoin and Heparin in Patients With Proven Scar Development

Not Applicable
Completed
Conditions
Cicatrix
Interventions
First Posted Date
2016-03-15
Last Posted Date
2016-10-04
Lead Sponsor
Suleymaniye Birth And Women's Health Education And Research Hospital
Target Recruit Count
120
Registration Number
NCT02708628
Locations
🇹🇷

Suleymaniye Birth And Women's Health Education And Research Hospital., Istanbul, Turkey

Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa

Phase 3
Terminated
Conditions
Epidermolysis Bullosa
Interventions
First Posted Date
2016-02-01
Last Posted Date
2019-09-27
Lead Sponsor
Scioderm, Inc.
Target Recruit Count
152
Registration Number
NCT02670330

ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Phase 3
Completed
Conditions
Epidermolysis Bullosa
Interventions
Drug: Placebo (SD-101-0.0) cream
First Posted Date
2015-03-10
Last Posted Date
2020-04-09
Lead Sponsor
Scioderm, Inc.
Target Recruit Count
169
Registration Number
NCT02384460
© Copyright 2025. All Rights Reserved by MedPath